These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 14736826

  • 1. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
    Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S.
    J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.
    Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E.
    Scand J Clin Lab Invest; 2004 Feb; 64(5):511-22. PubMed ID: 15276916
    [Abstract] [Full Text] [Related]

  • 7. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
    Benöhr P, Henkel V, Speer R, Vogel U, Sotlar K, Aydeniz B, Reiser A, Neubauer H, Tabiti K, Wallwiener D, Clare SE, Kurek R.
    Anticancer Res; 2005 Feb; 25(3B):1895-900. PubMed ID: 16158923
    [Abstract] [Full Text] [Related]

  • 8. Multiplexed tandem polymerase chain reaction identifies strong expression of oestrogen receptor and Her-2 from single, formalin-fixed, paraffin-embedded breast cancer sections.
    Thompson EW, Warton K, Blick T, Wafai R, Hill P, Stanley K.
    Pathology; 2010 Feb; 42(2):165-72. PubMed ID: 20085519
    [Abstract] [Full Text] [Related]

  • 9. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
    Ridolfi RL, Jamehdor MR, Arber JM.
    Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H.
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
    Monego G, Arena V, Maggiano N, Costarelli L, Crescenzi A, Zelano G, Amini M, Capelli A, Carbone A.
    Scand J Clin Lab Invest; 2007 Feb; 67(4):402-12. PubMed ID: 17558895
    [Abstract] [Full Text] [Related]

  • 16. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A, Xu B, Ayata G, Baiyee D, Wallace J, Wertheimer M, Edmiston K, Khan A.
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [Abstract] [Full Text] [Related]

  • 17. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
    Cuadros M, Talavera P, López FJ, García-Peréz I, Blanco A, Concha A.
    Pathobiology; 2010 Jun; 77(1):38-45. PubMed ID: 20185966
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.
    Seth RM, Burger AM, Kahn HJ.
    Anticancer Res; 2006 Jun; 26(2A):927-31. PubMed ID: 16619488
    [Abstract] [Full Text] [Related]

  • 19. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
    Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL.
    Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
    [Abstract] [Full Text] [Related]

  • 20. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.